These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 25822283)

  • 1. Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir.
    Kirby BJ; Symonds WT; Kearney BP; Mathias AA
    Clin Pharmacokinet; 2015 Jul; 54(7):677-90. PubMed ID: 25822283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Pharmacokinetics and Pharmacodynamics of Ledipasvir/Sofosbuvir, a Fixed-Dose Combination Tablet for the Treatment of Hepatitis C.
    German P; Mathias A; Brainard D; Kearney BP
    Clin Pharmacokinet; 2016 Nov; 55(11):1337-1351. PubMed ID: 27193156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of Daclatasvir, Sofosbuvir, and GS-331007 in a Prospective Cohort of Hepatitis C Virus-Positive Kidney Transplant Recipients.
    Schrezenmeier E; Hoffmann F; Jaeger C; Schrezenmeier J; Lisec J; Glander P; Algharably E; Kreutz R; Budde K; Duerr M; Halleck F
    Ther Drug Monit; 2019 Feb; 41(1):53-58. PubMed ID: 30422962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-Drug Interactions between Sofosbuvir and Ombitasvir-Paritaprevir-Ritonavir with or without Dasabuvir.
    King JR; Dutta S; Cohen D; Podsadecki TJ; Ding B; Awni WM; Menon RM
    Antimicrob Agents Chemother; 2016 Feb; 60(2):855-61. PubMed ID: 26596948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sofosbuvir (Sovaldi°). Active against hepatitis C virus, but evaluation is incomplete .
    Prescrire Int; 2015 Jan; 24(156):5-10. PubMed ID: 25734194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HCV Genotype 6a Escape From and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models.
    Pham LV; Ramirez S; Gottwein JM; Fahnøe U; Li YP; Pedersen J; Bukh J
    Gastroenterology; 2018 Jun; 154(8):2194-2208.e12. PubMed ID: 29454794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of hepatitis C virus replication by GS-6620, a potent C-nucleoside monophosphate prodrug.
    Feng JY; Cheng G; Perry J; Barauskas O; Xu Y; Fenaux M; Eng S; Tirunagari N; Peng B; Yu M; Tian Y; Lee YJ; Stepan G; Lagpacan LL; Jin D; Hung M; Ku KS; Han B; Kitrinos K; Perron M; Birkus G; Wong KA; Zhong W; Kim CU; Carey A; Cho A; Ray AS
    Antimicrob Agents Chemother; 2014; 58(4):1930-42. PubMed ID: 24419349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir.
    Tong X; Le Pogam S; Li L; Haines K; Piso K; Baronas V; Yan JM; So SS; Klumpp K; Nájera I
    J Infect Dis; 2014 Mar; 209(5):668-75. PubMed ID: 24154738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sofosbuvir-velpatasvir: A single-tablet treatment for hepatitis C infection of all genotypes.
    Miller MM
    Am J Health Syst Pharm; 2017 Jul; 74(14):1045-1052. PubMed ID: 28687550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and in vitro resistance to GS-9669, a thumb site II nonnucleoside inhibitor of the hepatitis C virus NS5B polymerase.
    Dvory-Sobol H; Voitenleitner C; Mabery E; Skurnac T; Lawitz EJ; McHutchison J; Svarovskaia ES; Delaney W; Miller MD; Mo H
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6599-606. PubMed ID: 25155588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic and pharmacokinetic evaluation of the combination of daclatasvir/sofosbuvir/ribavirin in the treatment of chronic hepatitis C.
    Rivero-Juarez A; Brieva T; Frias M; Rivero A
    Expert Opin Drug Metab Toxicol; 2018 Sep; 14(9):901-910. PubMed ID: 30058394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nucleoside Inhibitors of Hepatitis C Virus NS5B Polymerase: A Systematic Review.
    Xie Y; Ogah CA; Jiang X; Li J; Shen J
    Curr Drug Targets; 2016; 17(13):1560-76. PubMed ID: 26648061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sofosbuvir for the treatment of chronic hepatitis C virus infection.
    Temesgen Z; Talwani R; Rizza SA
    Drugs Today (Barc); 2014 Jun; 50(6):421-34. PubMed ID: 24983590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological evaluation of deuterated sofosbuvir analogs as HCV NS5B inhibitors with enhanced pharmacokinetic properties.
    Ao W; Ma X; Lin Y; Wang X; Song W; Wang Q; Zhang X; Xu H; Zhang Y
    J Labelled Comp Radiopharm; 2019 May; 62(5):215-229. PubMed ID: 30827031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sofosbuvir in the treatment of chronic hepatitis C: new dog, new tricks.
    Abraham GM; Spooner LM
    Clin Infect Dis; 2014 Aug; 59(3):411-5. PubMed ID: 24748524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection.
    Gane EJ; Stedman CA; Hyland RH; Ding X; Svarovskaia E; Subramanian GM; Symonds WT; McHutchison JG; Pang PS
    Gastroenterology; 2014 Mar; 146(3):736-743.e1. PubMed ID: 24262278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sofosbuvir/velpatasvir fixed-dose combination for the treatment of chronic hepatitis C virus infection.
    Nehra V; Rizza SA; Temesgen Z
    Drugs Today (Barc); 2017 Mar; 53(3):177-189. PubMed ID: 28447075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sofosbuvir and Ribavirin Liver Pharmacokinetics in Patients Infected with Hepatitis C Virus.
    Babusis D; Curry MP; Kirby B; Park Y; Murakami E; Wang T; Mathias A; Afdhal N; McHutchison JG; Ray AS
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29439971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, pharmacodynamics, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor, following multiple ascending doses in patients with chronic hepatitis C infection.
    Lawitz E; Rodriguez-Torres M; Denning JM; Albanis E; Cornpropst M; Berrey MM; Symonds WT
    Antimicrob Agents Chemother; 2013 Mar; 57(3):1209-17. PubMed ID: 23263000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS5A Inhibitor Ledipasvir.
    Cheng G; Tian Y; Doehle B; Peng B; Corsa A; Lee YJ; Gong R; Yu M; Han B; Xu S; Dvory-Sobol H; Perron M; Xu Y; Mo H; Pagratis N; Link JO; Delaney W
    Antimicrob Agents Chemother; 2016 Jan; 60(3):1847-1853. PubMed ID: 26824950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.